Douglas Holder PHRI Endowed Chair in Interventional Cardiology
Professor of Medicine, McMaster University
Director, Interventional Cardiology Hamilton Health Sciences
Senior Scientist, Population Health Research Institute
McMaster University
McMaster Unviersity
Dr. Shamir Mehta is the Douglas Holder PHRI Endowed Chair in Interventional Cardiology and Professor of Medicine at McMaster University. He is the Director of the Interventional Cardiology fellowship program at Hamilton Health Sciences and Senior Scientist at the Population Health Research Institute. He completed medical school, internal medicine/cardiology residency and interventional cardiology training at the University of Toronto, followed by research training and a Master’s in Health Research Methodology at McMaster University. He was the recipient of a CIHR New Investigator Award and was named one of Canada’s Top 40 Under 40.
He co-chairs the Canadian Cardiovascular Society Antiplatelet Therapy Guidelines. He has supervised the training over >30 interventional cardiologists in Canada and globally. His research focuses on the role of percutaneous invasive therapies in patients with acute coronary syndromes, the evaluation of novel antithrombotic therapies and structural heart interventions. Dr. Mehta also leads the percutaneous mitral and tricuspid valve repair programs at HHS.
Dr. Mehta has published over 250 articles and holds peer-review operating grants from the CIHR and industry. He has led practice-changing trials evaluating antiplatelet therapy in patients with ACS, including the PCI-CURE study establishing the benefit of P2Y12 inhibitor in patients with ACS undergoing PCI and the 25,000 patient CURRENT-OASIS 7 trial evaluating aspirin and clopidogrel dosing. He leads PREMISE, a Canadian multicenter registry of patients undergoing percutaneous mitral valve repair with Mitraclip. He has led landmark randomized trials of pragmatic interventions in ACS, including TIMACS evaluating optimal timing of invasive intervention in >3,000 patients, RIVAL, establishing a radial versus femoral artery approach, and the COMPLETE trial evaluating a strategy of complete revascularization in >4,000 patients with STEMI and multivessel disease. The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as one of its Most Notable Articles of 2019.
Disclosure information not submitted.
Saturday, October 28, 2023
15:15 – 16:15 EST